



Institutional Biosafety Committee

CDC Institutional Biosafety Committee (IBC) Meeting Minutes

Date: April 17, 2026

Time: 10:30 AM – 12:00 PM

Location: MS Teams meeting

Member	Attendance	Member	Attendance
1. NCEZID/DVBD1	☒	13. NCEZID/DCLSR2	☒
2. NCIRD/DVD	☒	14. IOD/OLSS3	☒
3. NCEZID/DHCPP1	☒	16. NCEZID/DCLSR3	☐
4. IOD/OLSS1	☒	17. NCEZID/OD	☒
5. OCOO/OSSAM/OHC	☐	18. IOD/OLSS4	☒
6. NCEZID/DVBD2	☒	19. NCHHSTP/DHP2	☒
7. IOD/OLSS2	☐	20. Outside Member/Atlanta1	☒
8. NCHHSTP/DHP1	☒	21. Outside Member/Atlanta2	☒
9. NCHHSTP/DTE	☐	22. Outside Member/Fort Collins	☒
10. NCIRD/ID	☒	23. Outside Member/Puerto Rico	☐
11. NCIRD/CORVD	☒	24. CDC/GHC/OD	☒
12. NCEZID/DCLSR1	☒	Visitor(s)	6

Agenda

1. **10:31 am EST**- Welcome and quorum confirmation
2. Review and approval of **March 20, 2026** Meeting Minutes
3. Review of IBC registrations:
 - 1) IBC-2025-256 Renewal
 - 2) IBC-2026-300 Renewal
 - 3) IBC-2026-301 Renewal
 - 4) IBC-2026-312 Renewal
4. Other Business

Review of IBC Registrations

1. IBC-2025-256 Renewal

General Project Description: The DHP Laboratory Branch uses nonhuman primates to conduct preclinical investigations of human immunodeficiency virus (HIV) prevention strategies. Such models are used to estimate the safety and efficacy of biomedical preventions against HIV transmission, with the goal of facilitating translation of meritorious interventions into clinical trials. In preclinical models, simian/human immunodeficiency viruses (SHIVs) are commonly used to challenge macaques, via controlled routes of exposure, to evaluate the protective efficacy of candidate HIV interventions. SHIV-infected macaques also may be transferred between IACUC protocols to facilitate subsequent study reassignment(s) among Laboratory Branch investigators.

Approximate percentage of the viral genome used: >2/3

Applicable Sec of NIH Guidelines: III-D-1b, III-D-3, III-D-4b

Required biological containment level for the work to be implemented: BSL-2E

General Points Discussed:



- **Section 2.8a:** Confirm whether plasmid pSHIV AD8-EO is being propagated as a stock. If so, Section 3 should be revised accordingly to add *E. coli*.
- **Section 2.12:** If the plasmid pSHIV AD8-EO is being propagated, mark III-D-2 as "Yes."
- **Section 5:** Add a training certificate for the alternate POC.

Committee Action: Approved with changes

2. IBC-2025-300 Renewal

General Project Description: This project will generate cDNA cassettes containing specific genes from influenza viruses. These genes will be analyzed using genetic, biochemical, cell biological, and immunological assays to test their effect on the normal function of virus and host, in order to understand how influenza viruses infect, transmit, and cause disease, and with the aim of developing methods to prevent, treat, and predict influenza virus infections.

Approximate percentage of the viral genome used: <1/2

Applicable Sec of NIH Guidelines: III-D-2a, III-D-4, III-D-7

Required biological containment level for the work to be implemented: BSL-2, BSL-2E

General Points Discussed:

- **Section 1.3:** This section as written appears to be vague. Please include a paragraph at the top of this section to summarize what work has been done so far and what laboratory work remains to be completed.
- **Section 2.6:** Use *Aequorea Victoria* rather than jellyfish (too generic).
- **Section 2.8a:** The generic list should be updated with specific vectors that have been used. What lentivirus vectors/system was used. What baculovirus vectors were used. Mentioned in 1.3 but not listed here.
- **Section 2.8b:** Should be marked "Yes", as CRISPR is mentioned in section 1.3.
- **Section 2.9:** Does the IACUC protocol (3409YORFERC / 26-0660) listed in 2.9c cover DNA injections to express flu genes? If so, please describe it in Section 1.3.
- **Section 2.12:** Lentiviruses are mentioned in 1.3 so III-D-3a should be selected.
- **Section 3:** The entries in Section 3 should be consolidated: delete RDNA/RNA Host-837, specify whether lentivirus is used in animals, and add this information to RDNA/RNA Host-771.

Committee Action: Approved with changes

3. IBC-2025-301 Renewal

General Project Description: The purpose of this study is to understand how natural variations in influenza surface proteins (hemagglutinin and neuraminidase) alter serological recognition, and to help predict the effect of new natural mutations on natural and vaccine-induced immunity.

Approximate percentage of the viral genome used: >2/3

Applicable Sec of NIH Guidelines: III-D-2-a, Section III-D-3-a, III-D-4-b, III-D-7, Section III-F-8

Required biological containment level for the work to be implemented: BSL-2

General Points Discussed:

- **Section 2.9:** Mark as "No."
- **Section 3:** Reads like PR/8/34 is being used, however this is not true based on what is written in Section 1.3. Section 3 should include the RG viruses based on human H1N1, H3N2, H1N1pdm09 HA/NA on a PR8 backbone, not WT viruses. Merge RDNA/RNA Host-772 and RDNA/RNA Host-773 to reflect reverse genetics viruses.

Committee Action: Approved with changes



Institutional Biosafety Committee

4. IBC-2025-312 Renewal

General Project Description: The aim of this study is to produce chimeric anti-gp41 antibodies to support the implementation of quality management systems for avidity-based HIV incidence tests and other related HIV serologic tests, in alignment of World Health Organization Guidance. Capacity to manufacture unlimited amounts of standardized materials may eliminate the need to rely on HIV-positive specimen repositories, which are costly and non-standard.

Approximate percentage of the viral genome used: N/A

Applicable Sec of NIH Guidelines: III-D-4, III-F-4

Required biological containment level for the work to be implemented: BSL-2

General Points Discussed:

- **Section 1.3:** Confirm plans for ongoing propagation, storage of the construct, or plan to resume the work.
- **Section 2.7a:** Lists only hybridomas (should be murine), but 293T or CHO are not listed in this section though they are mentioned in Section 1.3. Please add them here or remove them from Section 1.3.
- **Section 2.9:** Mark as "No".
- **Section 2.12:** Uncheck III-D-4.
- **Section 3:** Include K12 strain.
- **Section 4:** Please include campus name and remove the room number.
- **Section 5:** Training certificate needed for the alternate.

Committee Action: Approved with changes

Other Business

- **Committee Rapporteur (CR)**
 - No CR volunteers for April meeting.
 - CR responsibilities were reviewed as defined in the 2026 IBC Charter:
 1. The role of Committee Rapporteur shall rotate among the voting members.
 2. The Committee Rapporteur shall lead discussion of IBC registrations during the full Committee meeting. This facilitation includes capturing any helpful feedback for remediation of the registration. If needed, the CR shall review all remediated versions and may request additional revisions through the Administrator until final approval is reached.
 - The committee deliberated over the CR role and the discussion will be reconvened at the next committee meeting in May.
- **Meeting adjourned at 12:09 PM**

Reynolds M Salerno, PhD

Director, Office of Laboratory Systems and Response